Oral bioavailability exceeding 150% of a matched subcutaneous dose is not a number the GLP-1 field has seen before. In a 30-person single-dose Phase 1a study, Rani Therapeutics‘ RT-114, a RaniPill Capsule loaded with the GLP-1/GLP-2 dual agonist PG-102, produced systemic exposure that surpassed the injection comparator rather than merely approaching it. That result matters because the dominant narrative around oral biologic delivery has been one of painful compromise. Oral semaglutide achieves roughly 0.8% bioavailability under controlled dosing conditions, with within-subject variability of 137%, which is why its oral tablet requires a proprietary absorption enhancer and strict fasting protocols just to function. RT-114’s early numbers sit in a categorically different register.
The pharmacokinetic profile adds texture to the bioavailability headline. Elimination half-life was 5.6 days for oral RT-114 versus 5.3 days for subcutaneous PG-102, a near-identical result that suggests the RaniPill capsule is delivering the intact peptide into systemic circulation rather than a degraded fragment. No adverse events were attributed to the capsule device itself. Treatment-related events, nausea, vomiting, diarrhea, were mild and transient, consistent with the known GLP-1/GLP-2 class profile. The clean device safety record is significant because any novel delivery mechanism introduces its own risk surface, and Rani’s capsule, which uses a small needle to inject drug directly into the intestinal wall, has now cleared that bar in this indication.
Because oral exposure exceeded subcutaneous levels by more than 50%, dose selection for the next phase requires re-evaluation rather than simple extrapolation. Rani is adding a 15-person cohort in which participants receive two sequential 12 mg oral doses (24 mg total administered), specifically to map the dose-concentration relationship before committing to a Phase 1b design. That repeat-dose Phase 1b study, targeting patients with obesity over eight weeks, is expected to begin later in 2026 with data in 2027. Rani and ProGen share development costs and future profits equally, with Rani leading development in the U.S., Canada, Europe, and Australia after a Phase 2 study begins.
The result that will define RT-114’s trajectory is not bioavailability in healthy volunteers but pharmacodynamic weight-loss signal in the Phase 1b obesity cohort. Bioavailability above the subcutaneous comparator is a necessary condition for efficacy, not a guarantee of it. Watch the eight-week body weight data from that study: it will tell the field whether RaniPill’s exposure advantage translates into clinically meaningful weight reduction at practical oral doses, or whether peptide delivery and receptor pharmacology diverge in ways the Phase 1a PK data cannot anticipate.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
